Related references
Note: Only part of the references are listed.The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
Michael J. Lipinski et al.
EUROPEAN HEART JOURNAL (2016)
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
Massimiliano Ruscica et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Local effects of human PCSK9 on the atherosclerotic lesion
Ilaria Giunzioni et al.
JOURNAL OF PATHOLOGY (2016)
Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure
Elzbieta Sucajtys-Szulc et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Michel Farnier et al.
ATHEROSCLEROSIS (2016)
Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature
Michalina Kolodziejczak et al.
ATHEROSCLEROSIS (2016)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Hagai Tavori et al.
CARDIOVASCULAR RESEARCH (2016)
Blood Brain Barrier Disruption in Diabetic Stroke Related to Unfavorable Outcome
Xinfeng Yu et al.
CEREBROVASCULAR DISEASES (2016)
Imbalanced cholesterol metabolism in Alzheimer's disease
Zhao Xue-shan et al.
CLINICA CHIMICA ACTA (2016)
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
John H. Boyd et al.
JOURNAL OF INNATE IMMUNITY (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Annie Demers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
Yiming M. Zhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
Jean-Mathieu Berger et al.
ATHEROSCLEROSIS (2015)
Effects of lipoprotein apheresis on PCSK9 levels
U. Julius et al.
ATHEROSCLEROSIS SUPPLEMENTS (2015)
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis
Amelie Bonnefond et al.
DIABETOLOGIA (2015)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
John J. P. Kastelein et al.
EUROPEAN HEART JOURNAL (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
The Cellular and Molecular Basis of Translational Immunometabolism
Giuseppe Danilo Norata et al.
IMMUNITY (2015)
Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
Quoc-Tuan Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
Rocco Romagnuolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
Mika Hori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
Yascara G. Luna Saavedra et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease A Prospective Observational Cohort Study
Jian-Jun Li et al.
MEDICINE (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?
Jay P. Patel et al.
NEURAL PLASTICITY (2015)
Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
Kyubok Jin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
Marcin Konarzewski et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
Sha Li et al.
ATHEROSCLEROSIS (2014)
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
H. Abujrad et al.
ATHEROSCLEROSIS (2014)
HDL in innate and adaptive immunity
Alberico Luigi Catapano et al.
CARDIOVASCULAR RESEARCH (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
Clearance of Plasma Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein Apheresis
P. B. Duell et al.
CIRCULATION RESEARCH (2014)
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins
Arjan J. Kwakernaak et al.
CLINICAL BIOCHEMISTRY (2014)
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Thomas A. Lagace
CURRENT OPINION IN LIPIDOLOGY (2014)
Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
Giovanni Corrao et al.
DIABETES CARE (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Isolation and characterization of the circulating truncated form of PCSK9
Bomie Han et al.
JOURNAL OF LIPID RESEARCH (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation
Gulam Hussain Syed et al.
JOURNAL OF VIROLOGY (2014)
PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day
Yan Q. Chen et al.
LIPIDS (2014)
Apoptosis in Alzheimer's Disease: An Understanding of the Physiology, Pathology and Therapeutic Avenues
M. Obulesu et al.
NEUROCHEMICAL RESEARCH (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bridging Lipid Metabolism and Innate Host Defense
Claudia dos Santos et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Keith R. Walley et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
Christian Werner et al.
VASCULAR PHARMACOLOGY (2014)
PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
Giuseppe Danilo Norata et al.
VASCULAR PHARMACOLOGY (2014)
Blood-Brain Barrier Disruption after Cardiac Surgery
J. G. Merino et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2013)
Hepatic Cholesterol Homeostasis Is the Low-Density Lipoprotein Pathway a Regulatory or a Shunt Pathway?
Allan D. Sniderman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
Minna T. Janis et al.
ATHEROSCLEROSIS (2013)
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
Emile Levy et al.
ATHEROSCLEROSIS (2013)
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Arjan J. Kwakernaak et al.
ATHEROSCLEROSIS (2013)
Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation
Kun Ling Ma et al.
CARDIOVASCULAR RESEARCH (2013)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Hagai Tavori et al.
CIRCULATION (2013)
Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
Hagai Tavori et al.
CIRCULATION RESEARCH (2013)
Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management
Sudarshan Balla et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Giuseppe Danilo Norata et al.
EUROPEAN HEART JOURNAL (2013)
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Tanja Kosenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease
A. Baragetti et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
Bertrand Cariou et al.
NUTRITION & METABOLISM (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
ApoER2 and VLDLr Are Required for Mediating Reelin Signalling Pathway for Normal Migration and Positioning of Mesencephalic Dopaminergic Neurons
Ahmed Sharaf et al.
PLOS ONE (2013)
Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy
Frederick Raal et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Apolipoprotein B Secretory Regulation by Degradation
Sven-Olof Olofsson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Emerging role of high density lipoproteins as a player in the immune system
Giuseppe Danilo Norata et al.
ATHEROSCLEROSIS (2012)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
Anna Albecka et al.
HEPATOLOGY (2012)
Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Vikas Sharotri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Michael T. Lipari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
Iris Postmus et al.
JOURNAL OF LIPID RESEARCH (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Chun-Yan Wu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Paul M. Ridker et al.
LANCET (2012)
Crosstalk between reverse cholesterol transport and innate immunity
Kathleen M. Azzam et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Oxidative stress and inflammation: Implications in uremia and hemodialysis
Carmelo Libetta et al.
CLINICAL BIOCHEMISTRY (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
Estelle Rousselet et al.
JOURNAL OF LIPID RESEARCH (2011)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Blood-Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease
Yi Yang et al.
STROKE (2011)
Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
Shelby Sullivan et al.
TRANSLATIONAL RESEARCH (2011)
Trypanosoma cruzi Utilizes the Host Low Density Lipoprotein Receptor in Invasion
Fnu Nagajyothi et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Triglyceride-Rich Lipoproteins and Plasma Lipid Transport
Richard J. Havel
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
Bertrand Cariou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
Cedric Langhi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
Alexis Baass et al.
CLINICAL CHEMISTRY (2009)
Cholesterol metabolism and pancreatic β-cell function
Michelle Fryirs et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis
Angela D. Armendariz et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Cell biology, regulation and inhibition of β-secretase (BACE-1)
Clare E. Hunt et al.
FEBS JOURNAL (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Self-association of human PCSK9 correlates with its LDLR-degrading activity
Daping Fan et al.
BIOCHEMISTRY (2008)
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
Mary Cabell Jonas et al.
EMBO REPORTS (2008)
The activation and physiological functions of the proprotein convertases
Nabil G. Seidah et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB
Daniel A. Blasiole et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Blood-brain barrier tight junction permeability and ischemic stroke
Karin E. Sandoval et al.
NEUROBIOLOGY OF DISEASE (2008)
Influence of low-density lipoprotein (LDL) receptor on lipid composition, inflammation and parasitism during Toxoplasma gondii infection
Luciane R. Portugal et al.
MICROBES AND INFECTION (2008)
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction
Sekar Kathiresan
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1
Claudio Costantini et al.
BIOCHEMICAL JOURNAL (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse
Cheryl D. Overton et al.
CIRCULATION RESEARCH (2007)
Ly-6C(hi) monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata
Filip K. Swirski et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Increased gene expression of liver SREBP-2 in experimental chronic renal failure
Michal Chmielewski et al.
ATHEROSCLEROSIS (2007)
Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-offunction PCSK9 genetic polymorphisms
Majambu Mbikay et al.
MEDICAL HYPOTHESES (2007)
Proapoptotic effects of NARC 1 (=PCSK9), the gene encoding a novel serine proteinase
Brendan Bingham et al.
CYTOMETRY PART A (2006)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Steve Poirier et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines
XZ Ruan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
How does hepatitis C virus enter cells?
Gundo Diedrich
FEBS JOURNAL (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons
S Patil et al.
NEUROSCIENCE LETTERS (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein
JHM Levels et al.
INFECTION AND IMMUNITY (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
K Ouguerram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Molecular mechanisms of lipid disorders in nephrotic syndrome
ND Vaziri et al.
KIDNEY INTERNATIONAL (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B
DL Gillian-Daniel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis
LW Chiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57B1/6 mice
N Herijgers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
